Robust Bayesian nonlinear mixed‐effects modeling of time to positivity in tuberculosis trials
- 19 July 2018
- journal article
- research article
- Published by Wiley in Pharmaceutical Statistics
- Vol. 17 (5) , 615-628
Abstract
Early phase 2 tuberculosis (TB) trials are conducted to characterize the early bactericidal activity (EBA) of anti‐TB drugs. The EBA of anti‐TB drugs has conventionally been calculated as the rate of decline in colony forming unit (CFU) count during the first 14 days of treatment. The measurement of CFU count, however, is expensive and prone to contamination. Alternatively to CFU count, time to positivity (TTP), which is a potential biomarker for long‐term efficacy of anti‐TB drugs, can be used to characterize EBA. The current Bayesian nonlinear mixed‐effects (NLME) regression model for TTP data, however, lacks robustness to gross outliers that often are present in the data. The conventional way of handling such outliers involves their identification by visual inspection and subsequent exclusion from the analysis. However, this process can be questioned because of its subjective nature. For this reason, we fitted robust versions of the Bayesian nonlinear mixed‐effects regression model to a wide range of TTP datasets. The performance of the explored models was assessed through model comparison statistics and a simulation study. We conclude that fitting a robust model to TTP data obviates the need for explicit identification and subsequent “deletion” of outliers but ensures that gross outliers exert no undue influence on model fits. We recommend that the current practice of fitting conventional normal theory models be abandoned in favor of fitting robust models to TTP data.Keywords
This publication has 26 references indexed in Scilit:
- Randomized Dose-Ranging Study of the 14-Day Early Bactericidal Activity of Bedaquiline (TMC207) in Patients with Sputum Microscopy Smear-Positive Pulmonary TuberculosisAntimicrobial Agents and Chemotherapy, 2013
- Optimizing Outpatient Serial Sputum Colony Counting for Studies of Tuberculosis Treatment in Resource-Poor SettingsJournal of Clinical Microbiology, 2012
- Phase II Dose-Ranging Trial of the Early Bactericidal Activity of PA-824Antimicrobial Agents and Chemotherapy, 2012
- Evaluation of Time to Detection of Mycobacterium tuberculosis in Broth Culture as a Determinant for End Points in Treatment TrialsJournal of Clinical Microbiology, 2010
- Early Bactericidal Activity and Pharmacokinetics of PA-824 in Smear-Positive Tuberculosis PatientsAntimicrobial Agents and Chemotherapy, 2010
- Model-Based Clustering of Non-Gaussian Panel Data Based on Skew-tDistributionsJournal of Business & Economic Statistics, 2010
- The BUGS project: Evolution, critique and future directionsStatistics in Medicine, 2009
- Biomarkers for tuberculosis disease activity, cure, and relapseThe Lancet Infectious Diseases, 2009
- A default conjugate prior for variance components in generalized linear mixed models (comment on article by Browne and Draper)Bayesian Analysis, 2006
- A new class of multivariate skew distributions with applications to bayesian regression modelsCanadian Journal of Statistics, 2003